Literature DB >> 19901172

Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes.

Jing He1, Sarah Farias, Oliver Martinez, Bruce Reed, Dan Mungas, Charles Decarli.   

Abstract

OBJECTIVES: To evaluate demographics, magnetic resonance imaging (MRI) measures, and vascular risk among mild cognitive impairment (MCI) subtypes.
DESIGN: Cross-sectional study.
SETTING: Both clinics and the community. PARTICIPANTS: A total of 153 subjects with MCI, 218 cognitively normal older individuals (controls), and 68 patients with Alzheimer disease. MAIN OUTCOME MEASURES: Classification of subjects with MCI according to current subtype diagnostic convention based on neuropsychological performance, estimates of vascular risk based on medical history, research MRI unless there was a specific contraindication, and apolipoprotein E genotype.
RESULTS: Of the 153 subjects with MCI, 65 were diagnosed with amnestic single-domain, 46 with amnestic multiple-domain, 27 with nonamnestic single-domain, and 15 with nonamnestic multiple-domain MCI. Analyses of control, MCI, and Alzheimer disease cases revealed significant differences in brain and hippocampal volumes between each group. Post hoc analyses of MRI measures among the MCI subtypes found that patients with amnestic single-domain MCI had significantly less brain atrophy and that hippocampal volume differed significantly from controls for the 2 amnestic forms of MCI. Apolipoprotein E genotype prevalence was significantly greater in the amnestic and nonamnestic subtypes of MCI. Conversely, the nonamnestic subtypes were more likely to have increased vascular risk and to be African American.
CONCLUSIONS: Amnestic forms of MCI appear to have demographic, genetic, and MRI findings suggestive of Alzheimer disease pathology, whereas the nonamnestic forms of MCI have findings suggestive of vascular disease. Importantly, however, all subjects with MCI showed evidence of brain injury, and the biological differences among subtypes are relatively subtle beyond the memory vs nonmemory groupings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901172      PMCID: PMC2909769          DOI: 10.1001/archneurol.2009.252

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  57 in total

Review 1.  Antihypertensive treatment and the prevention of dementia: further insights from the Syst-Eur trial.

Authors:  L Hansson
Journal:  J Hypertens       Date:  1999-03       Impact factor: 4.844

2.  Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images.

Authors:  C DeCarli; J Maisog; D G Murphy; D Teichberg; S I Rapoport; B Horwitz
Journal:  J Comput Assist Tomogr       Date:  1992 Mar-Apr       Impact factor: 1.826

3.  Local histogram correction of MRI spatially dependent image pixel intensity nonuniformity.

Authors:  C DeCarli; D G Murphy; D Teichberg; G Campbell; G S Sobering
Journal:  J Magn Reson Imaging       Date:  1996 May-Jun       Impact factor: 4.813

4.  The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease.

Authors:  J C Morris; S Edland; C Clark; D Galasko; E Koss; R Mohs; G van Belle; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

5.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

Authors:  K A Welsh; N Butters; R C Mohs; D Beekly; S Edland; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

6.  Predictors of brain morphology for the men of the NHLBI twin study.

Authors:  C DeCarli; B L Miller; G E Swan; T Reed; P A Wolf; J Garner; L Jack; D Carmelli
Journal:  Stroke       Date:  1999-03       Impact factor: 7.914

7.  Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers.

Authors:  H C Chui; J I Victoroff; D Margolin; W Jagust; R Shankle; R Katzman
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

Authors:  F Forette; M L Seux; J A Staessen; L Thijs; W H Birkenhäger; M R Babarskiene; S Babeanu; A Bossini; B Gil-Extremera; X Girerd; T Laks; E Lilov; V Moisseyev; J Tuomilehto; H Vanhanen; J Webster; Y Yodfat; R Fagard
Journal:  Lancet       Date:  1998-10-24       Impact factor: 79.321

10.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

View more
  34 in total

1.  Gray matter volume and dual-task gait performance in mild cognitive impairment.

Authors:  Takehiko Doi; Helena M Blumen; Joe Verghese; Hiroyuki Shimada; Hyuma Makizako; Kota Tsutsumimoto; Ryo Hotta; Sho Nakakubo; Takao Suzuki
Journal:  Brain Imaging Behav       Date:  2017-06       Impact factor: 3.978

2.  The contributions of MRI-based measures of gray matter, white matter hyperintensity, and white matter integrity to late-life cognition.

Authors:  J He; V S S Wong; E Fletcher; P Maillard; D Y Lee; A-M Iosif; B Singh; O Martinez; A E Roach; S N Lockhart; L Beckett; D Mungas; S T Farias; O Carmichael; C DeCarli
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

3.  Interactive effects of apolipoprotein E4 and diabetes risk on later myelinating white matter regions in neurologically healthy older aged adults.

Authors:  Jessica M Foley; David H Salat; Nikki H Stricker; Tyler A Zink; Laura J Grande; Regina E McGlinchey; William P Milberg; Elizabeth C Leritz
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-12-31       Impact factor: 2.035

4.  Synchronization during an internally directed cognitive state in healthy aging and mild cognitive impairment: a MEG study.

Authors:  María Eugenia López; Pilar Garcés; Pablo Cuesta; Nazareth P Castellanos; Sara Aurtenetxe; Ricardo Bajo; Alberto Marcos; Mercedes Montenegro; Raquel Yubero; Francisco del Pozo; Miguel Sancho; Fernando Maestú
Journal:  Age (Dordr)       Date:  2014-06

5.  Glucose Dysregulation Interacts With APOE-∊4 to Potentiate Temporoparietal Cortical Thinning.

Authors:  Jessica M Foley; David H Salat; Nikki H Stricker; Regina E McGlinchey; William P Milberg; Laura J Grande; Elizabeth C Leritz
Journal:  Am J Alzheimers Dis Other Demen       Date:  2015-05-24       Impact factor: 2.035

Review 6.  Type 2 diabetes and cognitive impairment: linking mechanisms.

Authors:  José A Luchsinger
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 7.  Should mild cognitive impairment be subtyped?

Authors:  Tiffany F Hughes; Beth E Snitz; Mary Ganguli
Journal:  Curr Opin Psychiatry       Date:  2011-05       Impact factor: 4.741

8.  Cognitive impairment in nondemented oldest-old: prevalence and relationship to cardiovascular risk factors.

Authors:  Carrie B Peltz; María M Corrada; Daniel J Berlau; Claudia H Kawas
Journal:  Alzheimers Dement       Date:  2011-11-04       Impact factor: 21.566

Review 9.  Clinically asymptomatic vascular brain injury: a potent cause of cognitive impairment among older individuals.

Authors:  Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment.

Authors:  Edmond Teng; Brian W Becker; Ellen Woo; Jeffrey L Cummings; Po H Lu
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-26       Impact factor: 2.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.